Ľubomír Lachváč
Objective: Paper makes a brief summary of relevant information concerning pharmacotherapy of benign prostate hyperplasia and informs about indications, effectiveness and adverse effects of various types of pharmacological treatment. Material and methods: Review of publications summarizes results of clinical studies, their metaanalysis (Cochrane) and guidelines of European Association of Urology and American Urological Association. Results: Treatment effectiveness of the alpha-blockers, 5-alpha-reductase inhibitors as well as their combination was confirmed in more randomized clinical studies as well as their metaanalyses. The European Association of Urology Guidelines recommend pharmacotherapy with alpha-blockers and/or 5-alpha-reductase inhibitors in symptomatic benign prostate hyperplasia not indicated for surgical treatment. Further studies are required before plant extracts can be recommended for the treatment of benign prostate hyperplasia. Conclusions: Pharmacotherapy has a place in the treatment of symptomatic benign prostate hyperplasia without imperative indications for surgery. It can be initiated concluding initial evaluation, discussion of treatment options with patient and his informed choosing of noninvasive therapy.